Fujita Hiroyuki, Meyer Norbert, Akdis Mübeccel, Akdis Cezmi A
Chem Immunol Allergy. 2012;96:30-38. doi: 10.1159/000331868. Epub 2012 Mar 13.
In allergic diseases, immune responses are induced by normally well-tolerated allergens, which result in chronic inflammation characterized by antibody secretion and T cell activation. For almost 100 years, allergen-specific immunotherapy (allergen-SIT) has been the potentially curative and antigen-specific method for the treatment of allergic diseases. Allergen-SIT alters the course of allergic diseases and can reduce allergic symptoms and medication use. The key mechanism behind allergen-SIT is the induction of peripheral T cell tolerance by altering the balance between Th cells and regulatory T cells. Both naturally occurring thymus-derived FOXP3(+)CD4(+)CD25(+) regulatory T cells and inducible type 1 regulatory T cells suppress the development of allergic diseases via several mechanisms including suppression of dendritic cells, Th cells, mast cells, eosinophils and basophils; suppression of inflammatory cell migration to tissues; and decrease of the ratio between allergen-specific IgE and IgG4 antibodies. These effects are mainly mediated by the suppressive cytokines IL-10 and TGF-β. Knowledge of this molecular basis is crucial to understanding the regulation of the immune response and their possible therapeutic applications for allergic diseases.
在过敏性疾病中,通常可被良好耐受的过敏原会引发免疫反应,导致以抗体分泌和T细胞活化特征的慢性炎症。近100年来,过敏原特异性免疫疗法(allergen-SIT)一直是治疗过敏性疾病的潜在治愈性和抗原特异性方法。Allergen-SIT改变过敏性疾病的病程,可减轻过敏症状并减少药物使用。Allergen-SIT背后的关键机制是通过改变辅助性T细胞(Th细胞)与调节性T细胞之间的平衡来诱导外周T细胞耐受。天然存在的胸腺来源的FOXP3(+)CD4(+)CD25(+)调节性T细胞和诱导性1型调节性T细胞均通过多种机制抑制过敏性疾病的发展,这些机制包括抑制树突状细胞、Th细胞、肥大细胞、嗜酸性粒细胞和嗜碱性粒细胞;抑制炎症细胞向组织的迁移;以及降低过敏原特异性IgE与IgG4抗体之间的比例。这些作用主要由抑制性细胞因子白细胞介素-10(IL-10)和转化生长因子-β(TGF-β)介导。了解这一分子基础对于理解免疫反应的调节及其在过敏性疾病中的可能治疗应用至关重要。